Scientists at the University of California, San Francisco and the University of California, Davis have completed the first clinical trial of a new cancer drug in pet cats, offering hope for a disease that has long been nearly impossible to treat. The study found 35 percent of the cats with squamous cell carcinoma who received treatment had their disease controlled with minimal side effects. The drug will likely be effective for humans with head and neck squamous cell carcinoma. The study was published today in Cancer Cell.
Experimental treatment saved a kitten’s life after he was found abandoned at a Sacramento park suffering from an illness that is usually fatal in cats.
Chunk was just a tiny kitten when he was brought to the UC Davis veterinary hospital where he was enrolled in a CCAH-funded clinical trial studying various treatments for ringworm.
The Veterinary Center for Clinical Trials at the UC Davis School of Veterinary Medicine welcomes Drs. Krystle Reagan, DVM, PhD, DACVIM (SAIM) and Robert Rebhun, DVM, PhD, DACVIM (Oncology) as new co-directors of the center.
Lily, a 9-month-old female Bengal cat, is now in remission from feline infectious peritonitis (FIP) thanks to clinical trials at the UC Davis veterinary hospital.
Scientists from the UC Davis School of Veterinary Medicine have launched new clinical trials focused on improving treatments for feline infectious peritonitis, or FIP, and are currently enrolling patients at the UC Davis veterinary hospital.
Each year, more than 6 million dogs in the US will be diagnosed with cancer. In fact, about half of all dogs over the age of 10 will eventually develop some form of cancer. This is always a stressful situation for the animals’ owners who must make complex and difficult decisions about how to treat their pet.
Thanks to a university-wide collaboration between veterinarians, physicians, researchers, and biomedical engineers, a groundbreaking clinical trial has been approved in human medicine to treat spina bifida with stem cells.
